11 months ago
Kapiva Secures $60M for Ayurveda Expansion
Kapiva, a company making Ayurveda products, just got a big boost with $60 million in new funding!
They plan to use the money to improve their products by doing more research, using new technology, and expanding their business around the world.
They want to combine ancient Ayurveda with modern science to create effective health solutions.
Kapiva's products are currently sold in stores and online, and they're also available on Amazon and Flipkart.
The company is already doing well, and they are looking to become a major global healthcare brand by expanding into new markets, especially the UK and Germany.
They aim to validate their products through clinical trials.
Kapiva, an Ayurveda brand, secured $60 million in funding.
Funds will be used for R&D, health-tech, manufacturing, and global expansion.
The company combines traditional Ayurveda with modern scientific methods.
Diabetes and sports nutrition supplements contribute 60% of revenue.
Kapiva is expanding globally, particularly in the UK and Germany.
- Who
- Kapiva, an Ayurveda brand
- What
- Secured $60 million in funding
- Where
- India, with expansion planned globally
- When
- Recently
- Why
- To boost R&D, health-tech, manufacturing, and global expansion
Key facts
- Funding Amount
- $60 million
- Lead Investors
- 360 One Asset, Vertex Growth
- Annual Recurring Revenue
- Over ₹550 crore
- Year-over-year Growth
- 80%
- Revenue from Diabetes & Sports Nutrition
- Approximately 60%
- Online Sales Contribution
- 35% (app & website)
- Offline Store Target
- 1 lakh by March 2026
Quotes
Ameve Sharma
Founder of Kapiva
“The vision for the organisation is, how do we combine authentic, traditional, high-quality Ayurveda with newer scientific methods and standardisation? Bringing in things like clinical validation, standardising on a molecular level, to deliver measurable benefit to our customers”
CNBC TV 18
“The majority of the round was actually secondary, where we exited some of our early investors and angels. This itself was a very good milestone for the organisation, because going through a complete investor cycle… puts it on its way to becoming a later stage company.”
CNBC TV 18
